Nuclear Factor Erythroid 2-Related Factor 2 (NFE2L2) Antibody
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
Nuclear Factor Erythroid 2-Related Factor 2 (NFE2L2) Antibody is a Rabbit polyclonal antibody for the detection of Human Nuclear Factor Erythroid 2-Related Factor 2 (NFE2L2).
Documents del producto
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Nuclear Factor Erythroid 2-Related Factor 2 (NFE2L2) |
| Host | Rabbit |
| Reactivity | Human |
| Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Size 1 | 50 µg |
| Size 2 | 100 µg |
| Form | Liquid |
| Tested Applications | ELISA, WB, IHC |
| Buffer | 0.01 M PBS, pH 7.4, 50% glycerol, 0.05% Proclin-300. |
| Availability | Shipped within 5-12 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q16236 |
| Gene ID | 4780 |
| NCBI Accession | NP_001138884.1 |
| Background | Antibody anti-NFE2L2 |
| Status | RUO |
Descripción
Related Products
Human NFE2L2 (Nuclear Factor, Erythroid Derived 2 Like 2) ELISA Kit
Ver Producto
Rat Nfe2l2 (Nuclear Factor, Erythroid Derived 2 Like Protein 2) ELISA Kit
Ver Producto
NFE2L2 antibody
NRF2, also named as NFE2L2, belongs to the bZIP family and CNC subfamily. It is a transcription activator that binds to antioxidant response(ARE) elements in the promoter regions of target genes. NRF2 is important for the coordinated up-regulation of genes in response to oxidative stress. It may be involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.Nrf2 is a key player in the regulation of genes encoding for many antioxidative response enzymes.The expression of NRF2 may be induced under oxidative stress(PMID:14567983).In lung cancer, Nrf2 activation in malignant cells has been associated with tumor progression and chemotherapy resistance(PMID:20534738). Identifying patients with abnormal NRF2 expression may be important for selection for chemotherapy in NSCLC.
Ver Producto